MediPharm Labs Raises Concerns About Poorly Qualified Dissident Nominees
The Dissident Nominees were listed and described in a dissident proxy circular filed on May 7, 2025 (the " Dissident Circular") and are expected to stand for election at the Company's Annual and Special Meeting of Shareholders on June 16, 2025.
The Board's overall concerns with the Dissident Nominees
Following an initial review, the MediPharm Board of Directors (the " Board") has identified a number of concerns about the qualifications of the Dissident Nominees both individually and collectively. These concerns include:
Insufficient experience in the cannabis and pharmaceutical sectors
Limited public company board experience
Interlocking relationships among the nominees
Troublesome track record of the lead dissident
Potential conflicts of interest
Limited career experience and skills
Lack of diversity
Chris Taves, Chair of MediPharm, comments:
"Serving as a director of a public company carries significant responsibility and requires substantial experience. As a whole, the Board must possess a wide range of specific skills in order to effectively carry out its fiduciary responsibilities, including amongst other things, adherence to proper corporate governance. While some of the Dissident Nominees have had relevant career experience, we are concerned that this group, collectively, does not have the mix of qualifications necessary to run a complex international business like MediPharm."
The Dissident Nominees include the following individuals:
Regan McGee
Scott Walters
David Lontini
Demetrios Mallios
John Fowler
Alan D. Lewis II
The Board's concerns about the Dissident Nominees can be summarized as follows.
Insufficient experience in the cannabis and pharmaceutical sectors
Only two of the Dissident Nominees, Mr. Fowler and Mr. Walters, have any experience in the cannabis sector. Their cannabis experience has primarily been in the recreational space, which is significantly different from the medical space where the Company's focus lies. The medical cannabis sector requires specialized understanding of pharmaceutical manufacturing standards, global regulatory compliance, and medical distribution channels — expertise which none of the nominees appear to possess. The Company's business is now seeing meaningful growth in the international markets, as a result of it building out its international medical business, where it has a clear competitive advantage and ability to create shareholder value. No Dissident Nominee appears to have any experience in the pharmaceutical sector, in which MediPharm operates.
Limited public company director experience
The Dissident Circular indicates that the Dissident Nominees currently serve as directors of five public companies. Of these, at least four appear to be non-operating companies or speculative entities that would not typically provide a director with opportunities to acquire the type of skills and experience relevant for an active, complex business like MediPharm. Those five companies generate a median revenue of zero, and have a combined market capitalization that is roughly equal to that of MediPharm. They include:
Check-Cap Ltd. (Mr. Lontini) is a reverse merger candidate with no revenue whose value is based primarily on its public listing and its declining cash balance.
Big Gold Inc. (Mr. Walters) is an exploration-stage mining company with a market capitalization below C$1 million.
Maxus Mining Inc. (Mr. Walters) is an exploration-stage mining company whose shares began to trade on the Canadian Securities Exchange on May 8, 2025.
Invent Ventures Inc. (Mr. Lewis) is "an incubator that builds, acquires, and invests in transformative businesses." Its market capitalization and annual revenue are both below USD$1 million, more than seven years after Mr. Lewis and Mr. Mallios became controlling shareholders of Invent through their firm, The Aeon Group, and began to serve personally as officers and directors.
Paragon Technologies Inc. (Mr. Lontini), a holding company with a market capitalization of approximately USD$15 million, appears to be the largest public company on the list. Mr. Lontini has been a director for less than six months.
The Board is not aware of Mr. McGee, who seeks to become Chairman of MediPharm, ever having served on a public company board of directors.
Interlocking relationships among the nominees
There are multiple instances of the Dissident Nominees working together at other companies, serving together on other boards and otherwise having close commercial ties. Such interlocked relationships could lead to groupthink, lack of independent thought, and decisions that may be influenced by factors external to the Company. Examples of interlock include the following:
Mr. Lewis and Mr. Mallios are both officers of The Aeon Group. In addition, Mr. Lewis is a director of Invent Ventures Inc., a company controlled by Aeon Group, and for which Mr. Mallios serves as CEO.
Mr. Lontini is Active Chairman, and Mr. Lewis is Chief Financial Officer, of Check-Cap Ltd., a company which has entered a Business Combination Agreement with Nobul AI Inc., a company where Mr. McGee serves as Chairman, CEO and controlling shareholder.
Mr. Fowler and Mr. Walters previously served together as directors and management of The Supreme Cannabis Company, Inc., and continue to collaborate on business interests at companies including Blaise Ventures Inc. and The BIG Concentrates Company.
The Canadian Coalition for Good Governance (" CCGG") recommends: "that a company's directors should be independent of each other. To maintain that independence, an issuer should implement a policy limiting interlocking board relationships … CCGG believes that too many interlocking board relationships create interconnected interests that could be harmful to director independence."
Troublesome track record of the lead dissident
Regan McGee, Apollo's Chairman and CEO and the lead dissident, has a troublesome track record and a career marked by conflict and controversy. Nobul Technologies Inc. (" Nobul Tech"), a wholly owned Apollo subsidiary where Mr. McGee serves as Chairman and CEO, has been marred by a lawsuit in which it sued several of its former directors and investors who alleged that Nobul Tech was misrepresenting the source of its revenues, and that Mr. McGee was siphoning funds for his personal use. In his dealings with MediPharm, Mr. McGee has engaged in pressure tactics to acquire MediPharm shares improperly, and also threatened and defamed directors of the Company, among other improprieties. The Board is doubtful about Mr. McGee's appropriateness for a director role at any public company.
As communicated in previous MediPharm news releases, Mr. McGee has offered no alternative vision for the Company, including who he considers fit to manage the Company. The Board understands that Mr. McGee has been communicating with former senior executives of the Company.
Potential conflict of interest
The Dissident Nominee Mr. Fowler serves as president of a company, Muskoka Grown Ltd. and was formerly its CEO. (Mr. Fowler was identified as "president and CEO" of Muskoka Grown in Apollo's Advance Notice letter sent to the Company on May 1, 2025, but by the time the Dissident Circular was published on May 7, 2025, he no longer held the CEO title.) As disclosed in the Dissident Circular, Muskoka Grown is a supplier of cannabis products to MediPharm and negotiates the commercial terms of such arrangement with the Company. The Board believes it would not be possible for Mr. Fowler to exercise independent judgement on potential transactions relating to the Company that would also benefit him in other ways personally.
Limited career experience and skills
Mr. Lontini landed his first public company director role in January 2024 and added a second director role in December 2024. Prior to these appointments, his experience offers little indication that he would be considered a qualified candidate to be a public company director.
The biography presented to shareholders when he first became a director at Check-Cap Ltd. in January 2024, stated he had "completed M&A transactions" and mentioned "senior leadership positions." Based on publicly available information, including Mr. Lontini's LinkedIn profile, it is unclear whether he has ever held an executive role at any operating company outside of those he founded. His profile lists his title as president or owner at three separate entities he founded, including a home renovation business, a soccer consulting agency and a consulting firm established the same month he first became a director.
Lack of diversity
The dissident slate includes no female nominees, contrary to established best practices in corporate governance, including diversity expectations outlined by the Canadian Securities Administrators, proxy advisors and institutional stewardship policies.
MediPharm's refreshed Board and highly qualified nominees
In contrast to the underqualified Dissident Nominees, MediPharm has proposed seven highly qualified individuals for election to the Board. These nominees include David Pidduck, Chris Halyk, Chris Taves, Shelley Potts, Emily Jameson, John Medland and Keith Strachan.
Ms. Jameson and Mr. Medland are first-time nominees to the MediPharm Board, and if elected, would be fully independent directors with no connections to any existing directors of the Company. In particular, the addition of Ms. Jameson and Mr. Medland reflects the Company's intent to deepen capital markets expertise and M&A execution capabilities, which are increasingly relevant as MediPharm scales internationally and evaluates strategic growth opportunities.
Details about the Company's nominees can be found in the Management Information Circular recently sent to shareholders and filed by the Company on the SEDAR+ website at www.sedarplus.ca. Shareholders are also encouraged to visit www.medipharmlabsagm.com for nominees' biographies and other up-to-date information on the matters relating to the Annual and Special Meeting.
In light of the Board's serious concerns about the Dissident Nominees' qualifications and suitability, shareholders are urged to vote only using the GREEN proxy or GREEN voting instruction form in support of all of the Company's nominees and resolutions.
Proxy materials are currently being mailed and should arrive in the coming days, no later than next week.
In the meantime, to ensure your vote is counted, shareholders are encouraged to proactively contact their broker to obtain their 16-digit control number associated with the GREEN management proxy. Once received, you can cast your vote by visiting www.medipharmlabsagm.com.
You may receive materials or outreach from the dissident — please disregard any such communications and vote only using the GREEN proxy in support of the Company's nominees.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA.
In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions.
The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
Shareholder Voting Assistance:
If you have any questions or require any assistance in executing your GREEN proxy or voting instruction form, please call Sodali & Co at:
North American Toll-Free Number: 1.888.777.2059
Outside North America, Banks, Brokers and Collect Calls: 1.289.695.3075
Email: [email protected]
North American Toll-Free Facsimile: 1.877.218.5372
For up-to-date information and assistance in voting please visit: www.medipharmlabsagm.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things: timing of the Annual and Special Meeting, the Company's future growth strategies and available M&A opportunities, creation of sustainable long term shareholder value, and the Company's competitive advantages. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs' continuous disclosure filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
SOURCE MediPharm Labs Corp.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Montfort Capital Announces Agreements to Sell Pivot Business, Repurchase Shares
TORONTO, Aug. 5, 2025 /CNW/ - Montfort Capital Corp. ("Montfort" or the "Company") (TSXV: MONT), today announced it has entered into an agreement dated August 1, 2025 (the " Pivot SPA") to sell Pivot Financial I Limited Partnership, Pivot Financial Services Inc. and 2862454 Ontario Inc. ("collectively, the " Pivot Group") to Pivot Endgame Corp. (the " Purchaser"), an affiliate of an arm's length, third-party investment fund, for a cash purchase price of $2,278,541 and the tendering of the Montfort IB Note (as defined below) back to the Company (the " Pivot Sale"), subject to customary closing conditions, lender consents, closing price adjustments and post closing working capital adjustments. The Company expects the Pivot Sale to close on September 12, 2025, subject to the approval of the TSX Venture Exchange (" TSXV"). The Company does not expect the Pivot Sale to require shareholder approval. As condition of the Pivot Sale, Montfort has also entered into a share purchase agreement (the " Flaro SPA") with Dan Flaro, president of the Pivot Group, to acquire and cancel 1,024,299 Series A, Class A Preferred Shares and 2,397,368 common shares in the capital of the Company (the " Repurchased Shares") for aggregate consideration of $584,070.54 (the " Flaro Purchase Price"), subject to adjustment if market value of the Repurchased Shares is less than the Flaro Purchase Price on closing of the Flaro SPA. The Flaro Purchase Price will be paid by Montfort on closing of the Flaro SPA by issuing a non-interest bearing promissory note (the " Montfort IB Note"), whereby the principal thereof will equal the market value of the Repurchased Shares on closing of the Flaro SPA. The Flaro SPA is expected to close immediately prior to closing of the Pivot SPA, subject to approval of the TSXV. The Flaro SPA is an exempt issuer bid pursuant to Section 4.7 of National Instrument 62-104 Take-Over Bids and Issuer Bids (" NI 62-104"). Dan Flaro, as president of the Pivot Group, is a "related party" under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (" MI 61-101") and the Flaro SPA is considered a "related party transaction" subject to the requirements of TSXV Policy 5.9 and MI 61-101. The Company has relied on the exemptions from the formal valuation and minority shareholder approval requirements under sections 5.5(a) and 5.7(a) of MI 61-101 on the basis that the value of the Repurchased Shares does not exceed 25% of the Company's market capitalization. Additional details regarding the terms of the Pivot Sale and the acquisition of the Repurchased Shares are set out in the Pivot SPA and Flaro SPA which will be filed on the Company's profile on SEDAR+ at Montfort will send a copy of the material change report to be filed in respect of the Pivot Sale to any of its securityholders upon request and without charge. About Montfort Capital Corp. Montfort builds and manages private credit portfolios that have focused investing strategies for the institutional and accredited investors markets. For further information, please visit Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Forward-Looking Information Certain statements contained in this press release constitute "forward-looking information" and "forward-looking statements", collectively "forward looking statements". All statements other than statements of historical fact may be forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "continue", "estimate", "designed", "expect", "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe" and similar expressions. These forward-looking statements include, but are not limited to: projected timing of closing the Pivot Sale and the Flaro SPA, the TSXV acceptance of Pivot Sale and Flaro SPA, and obtaining consent of Montfort's senior lender, Cortland Credit Lending Corporation. This forward-looking information is based on a number of material factors and assumptions including, but not limited to: stable interest rates and financing costs remaining consistent with current market conditions; no material adverse changes in general economic conditions in key markets; competitive positioning remaining stable in the Company's target markets; stability in the competitive landscape of the Company's businesses with no disruptive new market entrants; credit spreads in private lending markets remaining consistent with current market conditions; no significant changes in asset valuations that would impact collateral values; continued demand for private credit; ability to maintain current loan servicing capabilities and operational efficiencies; ability to maintain relationships with key capital providers, co-lenders and financial partners; and availability of external financing at reasonable rates. These assumptions should be considered carefully by readers. The forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements. These risks and uncertainties include, but are not limited to: lower than expected revenue growth in the Company's core business segments; potential for increased competition that could compress profit margins; possibility of higher operating costs than forecasted; risk of economic downturn affecting demand for the Company's services; unforeseen regulatory changes impacting the Company's business model and/or cost structure; failure to obtain approval from the TSXV for the Pivot Sale and the Flaro SPA; failure to obtain approval of Cortland Credit Lending Corporation for the Pivot Sale; deterioration of the loan portfolio of the Company and of the Pivot Group; and the Company being unable to continue as a going concern due to its inability to procure additional liquidity and / or financing on reasonable terms. We do not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws. Based on current available information, the Company believes that the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that those expectations will prove to be correct. The forward-looking statements in this press release are expressly qualified by this statement, and readers are advised not to place undue reliance on the forward-looking statements.
Cision Canada
an hour ago
- Cision Canada
Charlotte's Web 2025 Second Quarter Earnings Call and Webcast Notice
LOUISVILLE, Colo., Aug. 5, 2025 /CNW/ - (TSX: CWEB) (OTC: CWBHF) Charlotte's Web Holdings, Inc. (" Charlotte ' s Web" or the " Company") a botanical wellness innovation company and the market leader in cannabidiol (CBD) hemp extract wellness products, will report its 2025 second quarter results prior to market open on August 13, 2025. A conference call to review the results is scheduled for the same day at 11:00 A.M. Eastern Time. There are three ways to join the call: Register and enter your phone number at to receive an instant automated call back, or Dial 1-646-357-8785 or 1-800-836-8184 approximately 10 minutes before the conference call, or Listen to the live webcast online. Earnings Call Replay A recording of the call will be available through August 20, 2025. To listen to a replay of the earnings call please dial 1- 646-517-4150 or 1-888-660-6345 and provide conference replay ID 22439#. A webcast of the call will also be accessible through the investor relations section of the Company's website for an extended period of time. Subscribe to Charlotte's Web investor news. About Charlotte's Web Holdings, Inc. Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in Louisville, Colorado, is a botanical wellness innovation company and a market leader in hemp extract wellness that includes Charlotte's Web whole-plant full-spectrum CBD extracts as well as broad-spectrum CBD and cannabinoid isolates. The Company's hemp extracts have naturally occurring botanical compounds including cannabidiol ("CBD"), CBN, CBC, CBG, THC, terpenes, flavonoids, and other beneficial compounds. Charlotte's Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, calming, exercise recovery, immunity), CBN gummies, hemp-derived THC microdose gummies, functional mushroom gummies, CBD capsules, CBD topical creams, and lotions, as well as CBD pet products for dogs. Through its substantially vertically integrated business model, Charlotte's Web maintains stringent control over product quality and consistency with analytic testing from soil to shelf for quality assurance. Charlotte's Web products are distributed to retailers and healthcare practitioners throughout the U.S.A. and are available online through the Company's website at
Winnipeg Free Press
an hour ago
- Winnipeg Free Press
S&P/TSX composite starts the week on the rise while U.S. markets fall
TORONTO – Canada's main stock index started the trading week on an upswing while U.S. markets fell. The S&P/TSX composite index was up 426.23 points at 27,446.66. In New York, the Dow Jones industrial average was down 142.46 points at 44,031.18. The S&P 500 index was down 27.46 points at 6,302.60, while the Nasdaq composite was down 85.98 points at 20,967.61. The Canadian dollar traded for 72.52 cents US compared with 72.53 cents US on Friday. The September crude oil contract was down 80 cents US at US$65.49 per barrel. Monday Mornings The latest local business news and a lookahead to the coming week. The December gold contract was up US$15.80 at US$3,442.20 an ounce. This report by The Canadian Press was first published Aug. 5, 2025.
